Expression Of Aurora A And ALK Protein In Neuroblastic Tumors And Its Relationship With Clinical Feature

Research objective:To investigate the expression of Aurora kinase A(Aurora A)and anaplastic lymphoma kinase(ALK) protein in neuroblastic tumors and its relationship with clinical feature. Methods:Neuroblastic paraffin tissues and clinical data from 22 neuroblastic tumor patients(April.2008—June.2015) were collected. The control was from none-tumoral patients. Software SPSS 18.0 was used for statistical analysis.Try to find the clinical feature differences between the two different pathological type of neuroblastoma and ganglioneuroblastoma.And draw the survival curve to estimate the prognosis.Investigate the relationship of clinical index with recurrence. Results:(1)The strong expression of Aurora A and ALK protein were detected in the neuroblastic paraffin tissues,but no expression in non-tumoral patients’ bone marrow samples(P<0.01).(2)The expression of Aurora A was different in different pathologic types of ganglioneuroblastoma and neuroblastoma,and the differences were statistically significant(P<0.05).But ALK expresses have no differences among different clinical figures(P>0.05).(3)The catecholamine in urine is different between the two pathologic types( P < 0.05)(4)OS in ganglioneuroblastoma was longer than that in the neuroblastoma.(5)Clinical stage and blood NSE were associated with recurrence(P<0.05). Conclusion:(1)Aurora A and ALK protein expresses strongly in the neuroblastic tumors.(2)The expression of Aurora A protein is different in different pathological tussues of neuroblastic tumors and may serve as a prognositic indicator.(3)The catecholamine in urine is different between ganglioneuroblastoma and neuroblastoma.(4)Os in ganglioneuroblastoma is longer than that in the neuroblastoma.(5)Clinical stage and blood NSE are associated with neuroblastomic tumor’s recurrence.